PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-201.62%
Negative EBIT growth points to weakening core profitability. Benjamin Graham would question management efficiency.
-201.62%
Negative operating income growth means rising costs or falling revenues are eroding core profitability. Benjamin Graham would raise caution.
-128.59%
Negative net income growth shows profitability erosion. Benjamin Graham would worry about solvency and longer-term viability.
-127.78%
Negative EPS growth underscores deteriorating earnings per share. Benjamin Graham would worry about ongoing dilution or weakened profitability.
-127.78%
Negative diluted EPS growth suggests diluted shares grew or net income fell. Benjamin Graham would see this as a serious setback to shareholder value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.70%
OCF growth above 20% – Exceptional cash generation improvement. Warren Buffett might see if the net margin also rises in tandem.
37.70%
FCF growth above 20% – Very attractive to value investors. Warren Buffett would check if capital expenditures remain sensible to maintain this level.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.48%
10Y OCF/share CAGR above 15% – Outstanding long-term cash-generation growth. Warren Buffett would check if reinvestment needs remain manageable.
24.48%
5Y OCF/share CAGR above 15% – Very robust mid-term cash expansion. Warren Buffett would check if reinvestment fosters sustainable growth.
24.48%
3Y OCF/share CAGR above 15% – Rapid short-term expansion. Warren Buffett would see if this stems from genuine operational improvements vs. working-capital swings.
9.10%
10Y net income/share CAGR 7-10% – Solid. Seth Klarman might check if dividends or buybacks accompany the rising profits.
9.10%
5Y net income/share CAGR 7-10% – Decent. Seth Klarman would investigate cyclical recovery vs. stable expansions.
9.10%
3Y net income/share CAGR 5-10% – Reasonable. Seth Klarman would check if it’s consistent each year or if one year skews the average.
-301.87%
Negative 10Y equity/share CAGR indicates a long-term decline in book value. Benjamin Graham would be extremely cautious about net worth destruction.
-301.87%
Negative 5Y equity/share CAGR suggests net worth destruction. Benjamin Graham would see if failing profitability or large payouts cause it.
-301.87%
Negative 3Y equity/share CAGR means a near-term drop in book value. Benjamin Graham would be cautious unless restructured operations promise a future rebound.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.07%
Negative asset growth may reflect divestitures or depreciation outpacing new investments. Benjamin Graham wonders if shedding non-core assets improves focus or signals trouble.
-11.47%
Falling book value/share indicates net losses, large dividends, or intangible impairments. Benjamin Graham warns unless there’s a strategic reason.
6.41%
Debt up 5-10% yoy – Noticeable leverage. Howard Marks questions if the returns outstrip higher interest costs.
No Data
No Data available this quarter, please select a different quarter.
186.72%
SG&A growth above 15% – Aggressive expense expansion. Philip Fisher demands a compelling ROI argument for such heavy spending.